Editorial: slow progress to optimising <i>H. pylori</i> eradication treatment with antisecretory drugs-Reference-Cited by-同舟云学术

Editorial: slow progress to optimising H. pylori eradication treatment with antisecretory drugs

Published:2022-08-22 Issue:6 Volume:56 Page:1074-1075
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Gisbert Javier P.¹^ORCID,Hunt Richard H.²^ORCID

Affiliation:

1. Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS‐Princesa), Universidad Autónoma de Madrid (UAM), and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) Madrid Spain

2. Division of Gastroenterology and Farncombe Family Digestive Health Research Institute McMaster University Hamilton Ontario Canada

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.17142

Reference10 articles.

1. Clinical trial: seven‐day vonoprazan‐ versus 14‐day proton pump inhibitor‐based triple therapy for first‐line Helicobacter pylori eradication

2. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection

3. Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report

4. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community

5. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Editorial: slow progress to optimising H. pylori eradication treatment with antisecretory drugs—authorsʼ reply;Alimentary Pharmacology & Therapeutics;2022-08-22